Topic: Clinical Trial Results
Pluristem and Thermo Fisher will collaborate to scale up manufacturing of regenerative medicines, to build an industry capable of millions of doses.
Biogen and Eisai’s phase 2 Alzheimer’s trial has re-emerged, slowing clinical symptom decline and reducing amyloid plaque accumulation in the brain.
Alzheimer’s startup Cortexyme rounded up $76 million for a potentially first-in-class antibiotic treatment, while others struggle in the field.
Esperion’s phase 3 results of bempedoic acid showed it lowered cholesterol levels, but 13 deaths were also reported, causing shares to slide.
The study found the wearable device was no more effective than medication alone at reducing sudden cardiac death.
Through a new online tracker, AllTrials names sponsors who fail to report clinical trial results on time per the FDAAA Final Rule.
Almost 30% of the participants were alive 18 months after starting treatment on a combination of CCX872 and the chemotherapy regimen FOLFIRINOX.
SAGE-217 triggered near-immediate, fairly durable improvements in patients with major depressive disorder.
The IL-23 antibody easily outperformed J&J’s Stelara and AbbVie’s own Humira, setting it up to go before regulators next year.